Ming‐Huang Chen

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo et al. · The Lancet · 2023 · 891 citations · Full text

Urology, Surgical Oncology, Gastrointestinal Oncology +5

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

Do‐Youn Oh, Aiwu Ruth He, Mohamed Bouattour et al. · ˜The œLancet. Gastroenterology & hepatology · 2024 · 196 citations · Full text

Overall Survival, Gastrointestinal Oncology, Medicine +7

A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer

J.S. Chen, Chih‐Hung Hsu, Nai‐Jung Chiang et al. · Annals of Oncology · 2015 · 157 citations

Gastrointestinal Oncology, Medicine, Biliary Cancer +7

Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial

Jack Wang, Chen‐Yi Wu, Yi-Cheng Yeh et al. · Oncotarget · 2015 · 121 citations · Full text

Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma

Pei‐Chang Lee, Yee Chao, Ming‐Huang Chen et al. · Cancers · 2020 · 102 citations · Full text